Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. John’s wort vs. Paxil

This article was originally published in The Tan Sheet

Executive Summary

Dr. Willmar Schwabe Pharmaceuticals' St. John's wort extract WS 5570 is "at least as effective as" GlaxoSmithKline's antidepressant Paxil (paroxetine) "over six weeks of acute treatment in out-patients with moderate or severe unipolar major depression," a Schwabe-funded study finds. The results "support the use of [St. John's wort] as an alternative to standard antidepressants in moderate to severe depression, especially as well-tolerated," A. Szegedi, Charite Universitatsmedizin, Berlin, et al., report in the Feb. 11 British Medical Journal. The study's 251 participants, who ranged in age from 18-70, were randomized to either 900 mg/day WS 5570 or 20 mg paroxetine once daily for six weeks. Response to treatment was measured by change in score on the Hamilton scale from baseline to day 42. The lead author has received consultancy fees from the firm, and two other study authors are employees of Schwabe...

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts